Glioma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Denovo, Pfizer, Chimerix, AiVita, Ascletis, Immunomic, Roche, Vigeo

MLA

“Glioma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Denovo, Pfizer, Chimerix, AiVita, Ascletis, Immunomic, Roche, Vigeo.” M2 Presswire, 25 Oct. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.770206973&authtype=sso&custid=ns315887.

APA

Glioma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Denovo, Pfizer, Chimerix, AiVita, Ascletis, Immunomic, Roche, Vigeo. (2023, October 25). M2 Presswire.

Chicago

M2 Presswire. 2023. “Glioma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Denovo, Pfizer, Chimerix, AiVita, Ascletis, Immunomic, Roche, Vigeo,” October 25. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.770206973&authtype=sso&custid=ns315887.